Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
Date:5/6/2008

I Completed

Treatment of pain following abdominal

laparoscopic surgery 304 III Enrolling

Adult safety 351 III Enrolling

Pediatric safety 352 III Enrolling

Pediatric pharmacokinetics 102 I Enrolling

(1) Conducted by Bristol-Myers Squibb Company

Omigard(TM) Clinical Program Update

o Cadence currently expects to announce top-line data from CLIRS in the

second half of 2008 and, if the results are positive, submit an NDA for

Omigard to the FDA in the first half of 2009.

Conference Call and Webcast on May 6, 2008 at 5:30 a.m. Pacific Time (8:30 a.m. Eastern Time)

Cadence management will host a conference call on May 6, 2008 at 5:30 a.m. Pacific Time (8:30 a.m. Eastern Time) and interested investors may participate in the conference call by dialing 877-675-4750 (domestic) or 719-325-4865 (international). To access the webcast, please visit the company's website at http://www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
3. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
4. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
5. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
6. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
7. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
8. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
9. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
11. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... DUBLIN , Sept. 22, 2014 ... the "PCSK9 and Other Novel Hypercholesterolemia Drugs" ... indicate that there is a high cholesterol burden despite ... Out of all the available options, statins have been ... concluded that reduction of plasma LDL cholesterol (LDLC) is ...
(Date:9/22/2014)... 2014  Aethlon Medical, Inc. (OTCQB: AEMD), the ... infectious disease, cancer and other life-threatening conditions, disclosed ... (DARPA) has informed the Company that it plans ... four of a five-year $5.9 million contract that ... under DARPA,s Dialysis-Like Therapeutics (DLT) program. ...
(Date:9/22/2014)... , Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... and fiscal 2014 ended July 31, 2014 on Monday, September ... to discuss the results at 11:00 AM ET. Participating in ... Andrew A. Krakauer , President and CEO; Jorgen ... A. Sheldon , Senior Vice President, CFO and Treasurer; and ...
Breaking Medicine Technology:PCSK9 and Other Novel Hypercholesterolemia Drugs 2PCSK9 and Other Novel Hypercholesterolemia Drugs 3Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2
... N.J., Oct. 15 Watson Pharmaceuticals, Inc. (NYSE: ... Laboratories, Inc., has received approval from the United States ... Application (ANDA) for Amlodipine Besylate/Benazepril 5/20mg, 10/20mg, 2.5/10mg, and ... The ANDA was acquired as part of Watson,s acquisition ...
... Inc. (Nasdaq: REGN ) will webcast its ... Industry Conference on Friday, October 22, 2010.  The presentation ... may be accessed through the Company,s web site, ... version of the presentation will be available after the ...
Cached Medicine Technology:Watson's Generic Version of Lotrel ® Receives FDA Approval 2
(Date:9/22/2014)... new study pulls back the curtain on one of ... payment and income between physicians who perform operations, procedures ... to perception, the research indicates, the physician payment system ... procedure-performing doctors. , The new findings counter the widely ... minute explains why doctors who perform procedures often earn ...
(Date:9/22/2014)... HealthDay Reporter MONDAY, Sept. 22, 2014 (HealthDay ... care units (NICU) set up private rooms for parents to ... Researchers at one children,s hospital found that preemies gained weight ... NICU switched from the traditional "open-bay" layout to private rooms ... the journal Pediatrics , add to evidence that private ...
(Date:9/22/2014)... Up to 40 percent of patients undergoing breast cancer ... remove all the cancerous tissue in the initial operation. ... successfully tested a tool they developed that will help ... thereby decreasing the chances for repeat operations. ... of September 22, 2014 in the Proceedings of ...
(Date:9/22/2014)... ON (September 22, 2014) McMaster scientists have found ... new class of antibiotics. , Although dozens of ... at how a certain part of bacteria are created, ... it. , The discovery is important as there ... making the cures for infections ineffective. The World Health ...
(Date:9/22/2014)... New York, US (PRWEB) September 22, 2014 ... Heartbeat Experts’ perspectives on stakeholder management needs for the ... speak with Heartbeat Experts on stakeholder strategies for any ... clinically meaningful points of differentiation within an increasingly crowded ... , The impact of identifying community-based thought ...
Breaking Medicine News(10 mins):Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:The fine line between breast cancer and normal tissues 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2
... MONDAY, Jan. 16 (HealthDay News) -- Persistent pain, eating problems ... survivors of head and neck cancer, a new study finds. ... issue of the journal Archives of Otolaryngology -- Head ... were diagnosed with head and neck cancer from 1995 to ...
... ten Canadians cannot afford to take their prescription drugs as ... of British Columbia and the University of Toronto. ... Canadian Medical Association Journal ) is the first to examine ... drugs in Canada. Researchers from UBC,s Centre for Health Services ...
... most severe cases of Lupus (systemic lupus erythemathosus), an ... the activity of some critical genes of the immune ... Italian researchers at the Catholic University of Sacred Heart ... the accelerator of the car and boosts the pathological ...
... British Columbia have found a new way to block infection ... could lead to new therapies for those affected by this ... worldwide suffer from hepatitis C, the disease caused by chronic ... of the leading causes of liver cancer and liver transplant ...
... Scientists working at the Medical Research Council have identified ... pre-cancerous cells in the esophagus, a condition called Barrett,s ... these cells before they develop into esophageal cancer. These ... have important implications for patients and may help to ...
... -- Soccer players need to use the correct techniques ... redirect the ball -- to prevent possible brain injury, researchers ... between the sport and brain damage, Dr. Alejandro Spiotta and ... moving at high speeds when they come into contact with ...
Cached Medicine News:Health News:Many Head and Neck Cancer Survivors Face Eating Problems 2Health News:1 in 10 Canadians cannot afford prescription drugs: UBC study 2Health News:A genetic accelerator hits the gas on autoimmune diseases 2Health News:UBC researchers identify potential new therapy approach for hepatitis C 2Health News:Researchers use sugar to halt esophageal cancer in its tracks 2Health News:Heading Soccer Balls Could Injure Brain 2
... new thinking to address common problems associated ... mm diameter outer arthroscope sheath, the shorter, ... Videoscope has superior access and mobility in ... and especially in the elbow and ankle. ...
... is the second generation of the lens ... technology allows one-handed delivery of the C11UB ... colored plunger allows better visualization and is ... insertion. The modified 55-degree beveled tip eases ...
... Heart 2006 is a long-term Transtelephonic ... This device is the solution ... symptoms and their correlation to the ... it provides 2 lead loop recording ...
... cable and 4 metal chest electrodes ... 3-step procedure enabling a patient to ... lead ECG through a simple change ... seconds per lead and 10 seconds ...
Medicine Products: